MICHAEL MORNEAU
CIK 1517780 · VP, Finance and Administration · last filed 2021-01-19
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.04M
Companies
3
Total Filings
23
Lifetime Open-Market Net
-$549.3K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Viking Therapeutics, Inc. (VKTXW) Delisted | VP, Finance and Administration | 116,062 | $4.60 | $533.9K | -$199.3K | 15 | 2021-01-19 |
| VKTX | Chief Financial Officer | 67,000 | $30.38 | $2.04M | $0 | 3 | 2016-03-15 |
| Trius Therapeutics Inc (TSRX) Delisted | VP Finance & CAO | 32,545 | — | — | -$350.0K | 4 | 2013-07-12 |
Recent Filings · Page 2 of 3
23 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-05-31 | Viking Therapeutics, Inc. (VKTXW) Delisted | Sell (S) | −21,551 | -$199.3K | EDGAR |
| 2018-05-08 | Viking Therapeutics, Inc. (VKTXW) Delisted | Tax (F) | −7,616 | -$32.1K | EDGAR |
| 2018-01-23 | Viking Therapeutics, Inc. (VKTXW) Delisted | Grant (A) | +15,000 | $0 | EDGAR |
| 2017-05-05 | Viking Therapeutics, Inc. (VKTXW) Delisted | Tax (F) | −8,192 | -$11.0K | EDGAR |
| 2017-01-05 | Viking Therapeutics, Inc. (VKTXW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-03-15 | VKTX | Grant (A) | — | $0 | EDGAR |
| 2016-03-08 | VKTX | Grant (A) | — | $0 | EDGAR |
| 2015-05-06 | VKTX | Mixed | +77,404 | $98.7K | EDGAR |
| 2013-09-13 | — | Disp (D) | −14,070 | $0 | |
| 2013-07-12 | Trius Therapeutics Inc (TSRX) Delisted | Mixed | — | -$115.0K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.